About US

Hi, nice to meet you! This is us:
(Read more about us and our vision below.)

More About Us and Our Vision

John-Paul Taylor
The creation of the IC-DLB marks a pivotal moment in the global effort to better understand dementia with Lewy bodies (DLB) and improve outcomes for people living with this condition. Advances in research, diagnostics, and care, along with substantive growth in the DLB researcher community, have brought us to a point where a more formalised and collaborative structure is essential to drive the next phase of progress.
As Chair, I will champion a vision of growth with a focus on expanding our scientific knowledge, increasing the reach and impact of our collaborations, and strengthening the capacity of our community to respond collectively to the challenges ahead. The IC-DLB provides a unique opportunity to harmonise activities across borders, unify standards, and foster meaningful connections among clinicians, researchers, industry, advocacy groups, and people with lived experience. I will prioritise nurturing a culture of consensus and transparency, supporting the next generation of leaders in the field, and ensuring that the work of the consortium is driven by scientific excellence and a shared commitment to improving the lives of people living with DLB. Together, we will shape a vibrant, responsive, and forward-looking consortium that can deliver on the promise of this new era.

Evelien Lemstra
Dr Evelien Lemstra is a neurologist and clinical researcher at the Alzheimer Center, Amsterdam University Medical Centres, with over 20 years of experience in dementia and movement disorders, with a particular focus on Dementia with Lewy Bodies (DLB). Her research aims to improve the diagnosis and management of DLB and to deepen understanding of its position between Alzheimer’s and Parkinson’s diseases. In 2015, she launched the DEvELOP study, a longitudinal DLB cohort now including over 200 participants, embedded in the Amsterdam Dementia Cohort of more than 6,000 deeply phenotyped individuals. 
She leads a work package in the TAP-Dementia consortium, focused on translating novel biomarkers into clinical practice, particularly for mixed pathology. She serves on the steering committee of the European DLB Consortium and contributes to collaborative projects on clinical outcomes and biomarker development. She is also a member of the Executive Committee of the Alzheimer’s Association PIA-DLB, chairs the Cognitive Neurology group of the Dutch Neurology Society, and is part of the national dementia diagnosis and treatment guideline committee. She organizes a biannual national DLB conference and hosted the 8th International Lewy Body Dementia Conference in 2025. She is fully committed to the mission of the IC-DLB and its role in advancing global collaboration, research, and awareness in DLB. 

Simon Lewis
Simon Lewis is Professor of Cognitive Neurology at Macquarie University, Sydney where he is the Director of the Parkinson’s Disease Research Clinic and heads the NSW Movement Disorders Brain Donor program.  He has published extensively in the field of DLB, mentoring a significant number of Fellows and students.  He began the NextGen DLB community, organising international online webinars aimed at supporting and promoting the work of early career researchers who he believes hold the key to advancing the field. 
Most recently, he has proposed the formalisation of the International Consortium for DLB (IC-DLB), delivering a comprehensive set of guidelines to allow a working framework.  He has a vision for how integrated IC-DLB working groups will be able to capitalise on existing structures (e.g. research consortia, advocacy groups, industry), to facilitate broad collaborations and engage key stakeholders that will further advance the science, clinical care and future of DLB.

Jennifer Goldman
Dr Jennifer G. Goldman, MD, MS, is a Movement Disorders neurologist with specialty certification in Behavioral Neurology and Neuropsychiatry. She is internationally recognized for her clinical, research, and educational work in Lewy body dementia (LBD), focusing on neuropsychiatric aspects, improving treatments, and advancing multidisciplinary care. Dr. Goldman is an adjunct Professor at Barrow Neurological Institute and provides expert consulting through JPG Enterprises LLC. She previously served as the inaugural Section Chief for Parkinson’s and Movement Disorders at Shirley Ryan AbilityLab and held professorships at Northwestern and Rush University.
With over 130 publications and numerous research grants, Dr. Goldman has led key initiatives to develop consensus guidelines and outcome measures in Parkinson’s disease and LBD. She currently serves as Secretary-Elect for the International Parkinson and Movement Disorder Society and Chair of the Lewy Body Dementia Association (LBDA) Industry Advisory Council. She also serves on the LBDA Board of Directors. As a candidate for Executive Committee Member-at-Large for the International DLB Consortium, Dr. Goldman aims to foster collaboration among scientists, clinicians, and stakeholders to accelerate treatment advances. She brings extensive leadership experience and a commitment to excellence, education, and advocacy to support the consortium’s mission.

Annegret Habich
Dr Annegret Habich is a postdoctoral researcher at Karolinska Institute, Sweden. Her research revolves around trajectories of healthy and pathological ageing, with a focus on DLB. Using a multimodal approach, she investigates progression of brain network alterations to explore targets for future interventions. As an emerging leader in the field, she is actively engaged in the global research community and contributing to international initiatives in the field. As such, she coordinates transfer and sharing of MRI data for the European DLB consortium. Through her engagement in initiatives like the NextGen DLB webinars, the Alzheimer Association’s LBD PIA, and her work with the Lewy Body Association, she is dedicated to creating opportunities for early career researchers to showcase their work and expand their professional networks. As a board member of IC-DLB, she will continue these efforts to create a supportive, innovative, and globally connected research network that accelerates the progress toward effective treatments and inspires the next generation of LBD researchers.

Joe Kane
In recent years, I have complemented my clinical and research work with leadership and ambassadorial roles in our field. In addition to my research focus on LBD care, epidemiology, and biomarkers, I have played leading roles in global collaborative projects developing the DLB Core Outcome Set (COS) and LBD Domain Rating Scale.
As Chair of the ISTAART LBD Professional Interest Area (PIA), I have expanded our network through webinars, podcasts, publications, and social media, and have demonstrated my passion for welcoming and supporting early career researchers (ECRs). Through ISTAART and my role on the AAIC Scientific Committee, I have ensured LBD is represented in the world’s largest global dementia research community. If elected, I will aim to continue expanding the LBD network beyond its traditional borders, making it more inclusive and interdisciplinary, and to develop closer relationships between our diverse medical and scientific disciplines. I will work to create platforms that amplify the work of ECRs and researchers from low- and middle-income countries and strive to find ways to attract and retain ECR talent in our field. I will also support the integration of the voices of patients, care partners, funders, and voluntary sector organisations into the work of IC-DLB.

John O’Brien
As an academic old age psychiatrist who has worked in London, Melbourne, Newcastle and now Cambridge (UK), DLB is the main focus of my research. I have had the privilege of attending every International DLB Consortium meeting since the first in 1994. 
There has been much progress and growth in the field, but there is so much more to do. My vision for IC-DLB is that it will provide the key international focus and authoritative voice for DLB by bringing the scientific community together, championing greater research and, through translation, better clinical care. In doing so it will liaise with many other key stakeholders, including other professional and governmental organisations, guideline groups, other DLB consortia and industry.
Importantly, IC-DLB will provide the strong framework necessary for ensuring continuity of the excellent International Conferences and tackle key initiates as necessary, for example leading revisions to the DLB Consensus Diagnostic Criteria and catalysing other workstreams, workgroups and activities.
The consortium needs to be inclusive and embrace global diversity, through broad membership and geographical coverage and in interactions with others, most obviously the Alzheimer’s and Parkinson’s disease communities, and through public engagement. Growing and supporting early career researchers should be a major priority. Jon emphasizes the need for inclusivity and global representation, fostering connections with Alzheimer’s and Parkinson’s communities, encouraging public engagement, and, importantly, prioritizing the growth and support of early career researchers as future leaders in the field.connected research network that accelerates the progress toward effective treatments and inspires the next generation of LBD researchers.